The Embolization Particle Market Size was valued at USD 0.69 Billion in 2023. The Embolization Particle market industry is projected to grow from USD 0.78 Billion in 2024 to USD 1.98 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.21% during the forecast period (2024 - 2032). The rise of treatments that don’t cut into the body too much and many heart disease cases are the key market drivers enhancing market growth.
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Market CAGR for embolization particles is driven by the rising rates of cancer because particle embolization is an important advancement for the treatment of cancer and other malignancies. The increasing worldwide cancer incidence has influenced the development of the Embolization Particle industry. They are increasingly used to treat illnesses apart from cancer, such as vascular abnormalities and fibrosis. The market is being bolstered by factors such as the rapidly growing healthcare sector and the increasing attention paid by academic institutions to developing cutting-edge technological solutions for improved diagnostics and treatment modalities. Demand for embolization particles is expected to rise due to the issues mentioned above in the future.
Additionally, minimally invasive methods, such as embolization particle therapy, are gaining popularity among patients and medical professionals, which bodes well for the future of the market for related products. The rise in cancer rates worldwide and the introduction of new types of Embolization Particles are factors that should help the market expand in the next years. Moreover, leading companies continually release cutting-edge, highly efficient products, which contributes to developing the embolization particle market. The embolization cancer market is anticipated to expand in the coming years due to increasing expenditure on research and development and industry leaders’ introduction of new products. Governments and non-profit organizations are trying to raise public awareness of embolization cancer in some countries. Oncologists and other cancer specialists have recently been interested in embolization cancer research. Therefore, the increasing prevalence of embolization particles is fueling the expansion of the international market. For instance, Guerbet (FR0000032526 GBT) reports it's going more than treble its line of microcatheters and introducing a new line of guidewires, resulting in a wide range of interventional imaging and embolization solutions being offered. As a result, the demand for embolization particles is predicted to grow throughout the forecasted time due to the rising cancer cases. Thus, the driving factor is the embolization particle market revenue.
The embolization particle market segmentation, based on product type, includes radioembolization and drug-eluting beads. In 2022, the radioembolization segment led the embolization particle market in revenue because of their use in cancer therapy and aids in reducing the rate at which the disease progresses and relieving the symptoms it causes.
Figure 1: Embolization Particle Market by Application, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
The embolization particle market segmentation, based on application, includes oncology, peripheral vascular disease, and neurology. The oncology is anticipated to grow at a CAGR of 14.20% over the projected period, making up the largest market share. An oncologist is a medical professional that has chosen to focus their career on treating cancer. There are numerous subtypes of oncologists. These doctors can treat patients with cancer in many different parts of the body.
By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American embolization particle market will dominate Due to the strong economy, the huge growth of the healthcare field, the rise in the number of people with cancer, and the fact that research institutions are putting more and more effort into updating technology to find new and better ways to diagnose and treat people. The market is also growing because hospitals have different layouts, and there are a lot of skilled healthcare workers.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: EMBOLIZATION PARTICLEMARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review
Europe’s embolization particle market accounts for the second-largest market share because of developments in healthcare provision, which have improved patients' access to diagnosis and treatment, and because of increased consumer knowledge of the medicines offered. Further, the embolization particle market held the largest market share, and the UK embolization particle market was the fastest-growing market in the European region.
The Asia-Pacific embolization particle market is expected to grow at the fastest CAGR from 2023 to 2032 because more people need healthcare in developing countries like India. In addition, the government's focus on improving healthcare facilities and the surge in medical tourism is likely to fuel the expansion of the embolization particle market in this region. Moreover, China’s embolization particle market held the largest market share, and the Indian embolization particle market was the fastest-rising market in the Asia-Pacific region.
Embolization Particle Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development to expand their product lines, which will help the embolization particle market grow even more. There are some strategies for action that market participants are implementing to increase their presence around the world's footprint, with important market developments including new product launches, contractual agreements and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the embolization particle industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics manufacturer use in the embolization particle industry to benefit clients and increase the market sector. In recent years, the embolization particle industry has offered some of the most significant technological advancements. Major players in the Embolization Particle market, including Guerbet, Terumo, BTG International Ltd, Boston Scientific Corporation, Medtronic, Sirtex, Merit Medical, and others, are attempting to grow market demand by investing in research and development operations.
Terumo has dedicated 100 years to “Contributing to Society through Healthcare” and is a leader in medical technology worldwide. With its headquarters in Tokyo and offices worldwide, Terumo employs more than 30,000 people to offer cutting-edge medical solutions in more than 160 nations and territories. The company has supported healthcare since its beginnings as a Japanese thermometer producer. Its broad range of goods now includes peritoneal dialysis treatments, blood transfusion systems, diabetic care, and solutions for vascular intervention and cardio surgery. It also includes technologies for blood transfusion and cell therapy. The Cardiac and Vascular Company focuses on treating illnesses of the blood vessels throughout the body, including the vital organs of the heart and lungs. They offer oxygenators and heart-lung machines to maintain life in place of the heart and lungs during cardiac surgery, surgical grafts and stent-grafts to replace blood vessels damaged by disease, and interventional devices that allow treatment by accessing blood vessels through a catheter to treat regions of the body including the heart and brain. Terumo will continue to work to improve its value to patients, healthcare workers, and the general public. In January 2023, Terumo Corporation (TSE: 4543) and Kyowa Kirin Co., Ltd. (TSE: 4151) collaborated to create the drug-device combination product "G-Lasta® Subcutaneous Injection 3.6 mg BodyPod".
Merit Medical Systems, Inc., a prominent producer, and distributor of unique disposable medical devices used in interventional, diagnostic, and therapeutic procedures, especially in cardiology, radiology, cancer, critical care, and endoscopy, was founded in 1987. Merit provides services to client hospitals worldwide with a domestic and international sales force and a clinical support team of more than 500 people, with offices in South Jordan, Utah. Pearland, Texas; Richmond, Virginia. Aliso Viejo, California, Maastricht and Venlo, The Netherlands, Paris, France, Galway, Ireland, Beijing, China, Tijuana, Mexico, Joinville, Brazil, Ontario, Canada, Melbourne, Australia, Tokyo, Japan, Reading, the United Kingdom, Johannesburg, South Africa, and Singapore, Merit employs about 6,300 people worldwide. To build long-term value for our customers, employees, shareholders, and communities, we must be outwardly focused and committed to providing an unforgettable experience. In March 2023, Merit Medical Systems announced that the SwiftNINJA Steerable Microcatheter product line had been widened. There are new lengths of 150 cm and a 2.4F distal diameter option with a low profile.
Key Companies in the Embolization Particle Market include
Embolization Particle Industry Developments
May 2023: Merit Medical Systems, Inc. acquired the BioSentry® Biopsy Tract Sealant System and various dialysis catheter devices from AngioDynamics, Inc. for a total cash payment of $100 million. Merit also stated that it recently paid $32.5 million in cash to Bluegrass Vascular Technologies, Inc. for the Surfacer® Inside-Out® Access Catheter System.
June 2023: Terumo Aortic's worldwide Post-Approval Study (PAS), codenamed EXTEND, is focused on Thoraflex Hybrid, the only Frozen Elephant Trunk (FET) device approved by the US Food and Drug Administration (FDA) for the treatment of patients with complex aortic arch sickness.
December 2022: Sirtex Medical and Grand Pharmaceutical Group Limited have succeeded in getting their SIR-Spheres® Y-90 resin microspheres approved by the Chinese National Medical Products Administration. The first-ever effective selective internal radiation therapy (SIRT) surgery was carried out utilizing SIR-Spheres in China.
Radioembolization
Drug Eluting Beads
Oncology
Peripheral Vascular Disease
Neurology
North America
Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
| Report Attribute/Metric | Details |
| Market Size 2023 | USD 0.69 Billion |
| Market Size 2024 | USD 0.78 Billion |
| Market Size 2032 | USD 1.98 Billion |
| Compound Annual Growth Rate (CAGR) | 12.21% (2024-2032) |
| Base Year | 2023 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Application, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, Aircraft Type, and the Rest of the World |
| Countries Covered | The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Guerbet, Terumo, BTG International Ltd, Boston Scientific Corporation, Medtronic, Sirtex, Merit Medical |
| Key Market Opportunities | Developing the use of modern technology |
| Key Market Dynamics | An increasing number of clinical studies on Embolization Particles More people are learning about slightly invasive procedures |
Embolization Particle Market Highlights:
Frequently Asked Questions (FAQ) :
The embolization particle market size was valued at USD 0.69 Billion in 2023.
The market is projected to grow at a CAGR of 12.21% during the forecast period, 2024-2032.
North America had the largest share of the market.
The key players in the market are Guerbet, Terumo, BTG International Ltd, Boston Scientific Corporation, Medtronic, Sirtex, and Merit Medical.
The radioembolization category dominated the market in 2023.
Oncology had the largest share of the market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
